Clinical Trials for COVID-19 Vaccines and Therapies

ProSciento’s clinical research unit (CRU) in Chula Vista, California, is prepared to conduct clinical trials for COVID-19 in healthy subject populations. For more information about expedited enrollment and start start, please visit .


Clinical Trial and Patient Treatment Continuity 

During these unprecedented times, ProSciento’s top priorities are patient and staff safety and clinical trial data integrity. We’re pleased to announce that clinical research activities have resumed across our CRO multi-center studies in accordance to amended protocols in compliance with FDA guidance and state and local mandates and in coordination with our clients, partners, and vendors. Clinical research activities have also resumed at our specialty clinical research unit (CRU) in Southern California through amended protocols and strict on-site safety measures.

For clinical studies conducted at our early phase clinical research unit (CRU) in Chula Vista, California, we worked closely with sponsors and Institutional Review Boards to adapt procedures for treatment and trial continuity. Most studies quickly transitioned to amended protocols, including out-patient study and safety schedules. 

To ensure the safety of our staff and study participants, we have taken COVID-19 precautions extremely seriously. Safety measures instituted at our CRU include:

  • COVID-19 antigen and antibody testing protocols for staff and subjects
  • Six-foot social distancing protocol throughout facility
  • Clinic zoning restricted to 10 individuals per area with independent entrance, exit and air flow system
  • MERV-13 HVAC airflow filtration system
  • Temperature and symptoms triage prior to entry for staff and subjects
  • PPE for clinical staff and face clothes for subjects
  • Daily medical grade sanitation of clinic

During these challenging and uncertain times, we are grateful for our tremendous team, partners and clients as we work together swiftly and responsibly to ensure patient safety and treatment continuity in response to the impacts of COVID-19. Together, we remain committed to our mission of finding new treatments for diabetes, NASH, obesity and related metabolic diseases.

For questions or additional information, please contact us at